# Incyte (INCY) — Overview

INCY · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/incy

## Price

Last close $113.27 on Oct 15, 2026. 52-week range $86.17 – $129.93.

## Company profile

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

## Financials

| Metric | Value |
| --- | --- |
| Revenue (trailing twelve months) | $5.8B |
| Revenue (quarter) | $1.7B |
| Revenue growth (year over year) | 37.72% |
| Gross profit (trailing twelve months) | $5.6B |
| Gross margin | 96.78% |
| Net income (trailing twelve months) | $1.6B |
| Net income (quarter) | $585.6M |
| Net income growth (year over year) | 44.59% |
| Net margin | 27.71% |
| Return on equity | 30.67% |
| EPS (trailing twelve months) | $8.13 |
| Book value per share | $31.57 |
| P/E (trailing twelve months) | 14.2 |
| Price to book | 3.6 |
| Debt to assets | 19.41% |
| Payout ratio | 0.00% |
| Dividend yield | 0.00% |

## Frequently Asked Questions

### Is Incyte (INCY) profitable?

Yes. Incyte earned $1.6B in net income over the trailing twelve months, a net margin of 27.71%.

### How much revenue does Incyte (INCY) make?

Incyte generated $5.8B in revenue over the trailing twelve months, up 37.72% year over year.

### What is INCY's P/E ratio?

Incyte trades at 14.2 times trailing twelve-month earnings, on an EPS of $8.13.

### How do I buy stock in Incyte (INCY)?

INCY trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at [Light Horse Dashboard](https://portal.lighthorse.io), the trading API, or an [AI agent connected over MCP](/instructions/ai/claude). The trade panel on this page places the order once you are signed in.

## Similar Stocks

- [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock

---

Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).